MA28583B1 - Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents

Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale

Info

Publication number
MA28583B1
MA28583B1 MA29452A MA29452A MA28583B1 MA 28583 B1 MA28583 B1 MA 28583B1 MA 29452 A MA29452 A MA 29452A MA 29452 A MA29452 A MA 29452A MA 28583 B1 MA28583 B1 MA 28583B1
Authority
MA
Morocco
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
pyrimidine
Prior art date
Application number
MA29452A
Other languages
English (en)
French (fr)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28583(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28583B1 publication Critical patent/MA28583B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
MA29452A 2004-05-14 2006-11-14 Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale MA28583B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
MA28583B1 true MA28583B1 (fr) 2007-05-02

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29452A MA28583B1 (fr) 2004-05-14 2006-11-14 Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale

Country Status (27)

Country Link
EP (1) EP1751143A1 (zh)
JP (1) JP4099212B2 (zh)
KR (1) KR100886990B1 (zh)
CN (2) CN102127058A (zh)
AP (1) AP2241A (zh)
AR (1) AR049097A1 (zh)
AU (2) AU2005243397A1 (zh)
BR (1) BRPI0511138A (zh)
CA (1) CA2566707A1 (zh)
CR (1) CR8749A (zh)
EA (1) EA200601796A1 (zh)
EC (1) ECSP066997A (zh)
GE (1) GEP20104875B (zh)
GT (1) GT200500113A (zh)
IL (1) IL178828A0 (zh)
MA (1) MA28583B1 (zh)
MX (1) MXPA06011890A (zh)
NL (2) NL1029045C2 (zh)
NO (1) NO20064576L (zh)
NZ (1) NZ550448A (zh)
PA (1) PA8632601A1 (zh)
PE (1) PE20060240A1 (zh)
TN (1) TNSN06370A1 (zh)
TW (1) TWI303635B (zh)
UY (1) UY28894A1 (zh)
WO (1) WO2005111023A1 (zh)
ZA (1) ZA200608394B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009011090A (es) * 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
KR20100049068A (ko) * 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Ｐｋｃ 억제제로서의 시클릭 아민 치환된 피리미딘디아민
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2723961C (en) * 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Ｅｇ５阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NL1029045C2 (nl) 2006-06-02
AP2241A (en) 2011-06-01
PA8632601A1 (es) 2006-06-02
EA200601796A1 (ru) 2007-04-27
NL1031845A1 (nl) 2006-07-31
ECSP066997A (es) 2007-02-28
CA2566707A1 (en) 2005-11-24
PE20060240A1 (es) 2006-04-01
GT200500113A (es) 2006-01-10
UY28894A1 (es) 2005-12-30
JP2007537234A (ja) 2007-12-20
KR100886990B1 (ko) 2009-03-04
JP4099212B2 (ja) 2008-06-11
GEP20104875B (en) 2010-01-11
NO20064576L (no) 2006-11-07
MXPA06011890A (es) 2006-12-14
ZA200608394B (en) 2008-05-28
AP2006003790A0 (en) 2006-10-31
NZ550448A (en) 2010-11-26
AR049097A1 (es) 2006-06-28
NL1029045A1 (nl) 2005-11-15
CR8749A (es) 2006-12-05
TWI303635B (en) 2008-12-01
NL1031845C2 (nl) 2006-11-23
CN1953974A (zh) 2007-04-25
CN102127058A (zh) 2011-07-20
TNSN06370A1 (fr) 2008-02-22
AU2005243397A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
WO2005111023A1 (en) 2005-11-24
BRPI0511138A (pt) 2007-11-27
TW200539871A (en) 2005-12-16
AU2009238255A1 (en) 2009-12-03
EP1751143A1 (en) 2007-02-14
IL178828A0 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
NL1025067A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
NL1025071A1 (nl) Verbindingen voor de behandeling van abnormale celgroei.
EP1758854A4 (en) PYRROLIDIN-3-YLE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1807396A4 (en) 2-AMINOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP1740559A4 (en) 1,3,5-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
EP1951709A4 (en) IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2871365B1 (fr) Implant pour le traitement de la rectocele ou de la cystocele
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
EP1755581A4 (en) METHODS AND COMPOSITIONS FOR TREATING MYOCARDIAL CONDITIONS
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"
FR2868312B1 (fr) Patch pour le traitement des levres
UA80871C2 (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
FR2843015B1 (fr) Implant pour le traitement de la presbytie
FR2852252B1 (fr) Valve implantable pour le traitement de l'hydrocephalie
FR2851247B1 (fr) Methodes et compositions pour le traitement de pathologies degeneratives oculaires
FR2877028B1 (fr) Procede d'amenagement de combles
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2887539B1 (fr) Bio reacteur, pour le traitement des effluents par chenal d'aeration